CONDUIT PHARMACEUTICALS INC (CDT) Stock News
NASDAQ:CDT - Nasdaq - US20678X1063 - Common Stock
CDT Latest News and Analysis
Friday's session: top gainers and losers
These stocks are moving in today's session
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Curious about the most active stocks on Friday? Find out which stocks are dominating the market action!
These stocks are moving in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top gainers and losers in today's session.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
Get insights into the top gainers and losers of Friday's pre-market session.
Wednesday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!
Wednesday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!
These stocks are the most active in today's session
Tuesday's session: gap up and gap down stocks
Gap analysis on 2025-01-07: gap up and gap down stocks in today's session.
Curious about the stocks that are showing activity before the opening bell on Tuesday?
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Top movers in Monday's after hours session
Which stocks are moving after the closing bell on Monday?
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics Approach...
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing value
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders...
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors...
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive...
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the...
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will...
Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?
Conduit Pharmaceuticals stock is up on Wednesday alongside heavy trading following an invest update on CDT shares.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning!
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024
Conduit Pharmaceuticals just reported results for the second quarter of 2024.
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders...